When is Niagen Bioscience, Inc.'s (NAGE) next earnings report?

Niagen Bioscience, Inc.'s next earnings report is expected on July 25, 2026 (57 days away). View NAGE's historical earnings reactions and AI-powered earnings trade plan on Trend Edge at https://trendedge.app/asset/NAGE

What is Niagen Bioscience, Inc.'s (NAGE) market cap?

Niagen Bioscience, Inc. has a market cap of $302M, classifying it as a small-cap Healthcare stock. Trend Edge tracks NAGE's institutional ownership (47.5%), insider transactions, and proprietary indicators.

Is Niagen Bioscience, Inc. (NAGE) founder-led?

Yes — Niagen Bioscience, Inc. is founder-led. Current founder leadership: Frank Jaksch (Co-Founder & Chairman of the Board). Founder-led companies are tracked separately by Trend Edge as a proprietary indicator.

What is NAGE's Trend Edge Score?

NAGE's current Trend Edge Score is 0.0. The Trend Edge Score is a proprietary technical indicator combining weekly trend strength, momentum, and volume signals into a single value used to rank long position setups across thousands of tracked stocks.

How has NAGE historically reacted to earnings?

Over the last 65 earnings events, NAGE has averaged a 1.31% return in the week following earnings, with a 41.54% win rate. Best 1-week reaction: +86.25%. Worst: -23.54%. Full earnings reaction breakdown across gap, 1-day, 2-week, and 1-month timeframes available on Trend Edge.

What is the average analyst price target for NAGE?

4 Wall Street analysts have an average price target of $12.60 on NAGE, implying 229% upside from the current price of $3.83.

NAGE Stock Analysis — Niagen Bioscience, Inc. · Founder-Led

About Niagen Bioscience, Inc.

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercial… Read full Trend Edge analysis →

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: July 15, 2008
Headquarters: 10900 Wilshire Blvd, Los Angeles, CA, United States, 90024
Website: https://www.niagenbioscience.com
Employees: 117

Key Metrics

Current Price	$3.83
Market Cap	$302M
Float	52.4M
Shares Outstanding	79.6M
P/E (Forward)	14.58
P/E (TTM)	18.05
Price/Sales (TTM)	2.31
vs. Analyst Target	+229.0% to analyst PT
Profit Margin	14.29%
Operating Margin (TTM)	5.01%
Revenue (TTM)	$130M
Earnings Growth (YoY)	16.70%
Dividend Rate	None
Analyst Target Price	$12.60 (4 analysts)

Financial History

Annual Revenue & Earnings History

Year	Revenue	Net Income	Gross Profit	EBITDA
2020	$59.3M	-$19.9M	$35.3M	-$18.3M
2021	$67.4M	-$27.1M	$41.5M	-$25.4M
2022	$72.0M	-$16.5M	$42.8M	-$16.7M
2023	$83.6M	-$4.9M	$50.8M	-$3.9M
2024	$99.6M	$8.6M	$61.6M	$9.2M
2025	$129M	$17.4M	$83.2M	$15.7M

Recent Quarterly Revenue & Net Income

Quarter	Revenue	Net Income
Jun 2025	$31.1M	$3.6M
Sep 2025	$34.0M	$4.6M
Dec 2025	$33.8M	$4.1M
Mar 2026	$31.5M	$6.3M

Insider Ownership	29.3%
Institutional Ownership	47.5%
Short Float	10.3%
% of All Funds Holding	1.58%
Number of Funds Holding	130

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

Timeframe	SMA	Value	Trend Context
Weekly	10-Week SMA	$4.30	Near-term / short-term trend
Weekly	40-Week SMA	$6.19	Medium-term trend
Weekly	80-Week SMA	$7.23	Cyclical trend (business cycle)
Weekly	200-Week SMA	$4.18	Secular trend (multi-year)
Monthly	10-Month SMA	$6.39	Near-term monthly trend
Monthly	20-Month SMA	$7.05	Medium-term monthly trend
Monthly	40-Month SMA	$4.58	Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price Level	Type	Volume Ratio	Age
$9.10	resistance	1.38x	6 months ago
$14.40	resistance	1.19x	9 months ago
$1.70	support	4.24x	25 months ago

Historical Earnings Reactions (65 events)

Timeframe	Avg Return	Median	Win Rate	Best	Worst
Gap	0.71%	0.00%	41.54%	19.82%	-13.01%
1 Day	1.04%	0.29%	50.77%	67.91%	-19.42%
1 Week	1.31%	-2.44%	41.54%	86.25%	-23.54%
2 Weeks	2.61%	-3.16%	43.08%	95.42%	-23.74%
1 Month	4.10%	-3.43%	40.63%	128.74%	-40.00%

Next earnings: July 25, 2026 (57 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Month	Avg Return	Win Rate	Samples
Jan	6.0%	61.1%	18
Feb	12.3%	61.1%	18
Mar	-1.9%	33.3%	18
Apr	12.0%	55.6%	18
May	5.2%	58.8%	17
Jun	0.9%	52.9%	17
Jul	1.2%	44.4%	18
Aug	-1.7%	38.9%	18
Sep	-6.3%	33.3%	18
Oct	-7.3%	27.8%	18
Nov	14.0%	55.6%	18
Dec	19.7%	33.3%	18

Day-of-Week Tendencies

Day	Avg Return	Win Rate	Samples
Monday	0.59%	40.2%	845
Tuesday	0.39%	40.6%	928
Wednesday	0.28%	42.0%	924
Thursday	-0.02%	41.2%	906
Friday	0.93%	45.1%	903

Insider Transactions — Smart Summary

Total insider ownership: 29.3%

Founder-led management: Frank Jaksch (Co-Founder & Chairman of the Board)

12-Month Insider Activity Summary

Total Filings	1
Net Value	+$45,616.426
Net Shares Change	6,685
% of Float	0.0%
C-Suite Filings	1
Clusters Detected	0

Key Insiders

Name	Title	Net Value	Filings	Activity
Pamir Ozan	Chief Financial Officer	+$45,616.426	1	2 buy

Significant Filings

Date	Insider	Title	Net Value	Price After
2025-11-17	Pamir Ozan	Chief Financial Officer	+$45,616.426	Transaction at $6.83, now -43.9%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Niagen Bioscience, Inc. (NAGE) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for NAGE on Trend Edge →

NAGE — Niagen Bioscience, Inc.

About Niagen Bioscience, Inc.

Trend Edge Proprietary Indicators

Key Metrics

Financial History

Annual Revenue & Earnings History

Recent Quarterly Revenue & Net Income

Ownership & Float

Current Moving Averages

Volume Shelves — Support & Resistance

Historical Earnings Reactions (65 events)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Day-of-Week Tendencies

Top Institutional Holders

Insider Transactions — Smart Summary

12-Month Insider Activity Summary

Key Insiders

Significant Filings

AI Consult Analysis

NAGE — Niagen Bioscience, Inc.

About Niagen Bioscience, Inc.

Trend Edge Proprietary Indicators

Key Metrics

Financial History

Annual Revenue & Earnings History

Recent Quarterly Revenue & Net Income

Ownership & Float

Current Moving Averages

Volume Shelves — Support & Resistance

Historical Earnings Reactions (65 events)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Day-of-Week Tendencies

Top Institutional Holders

Insider Transactions — Smart Summary

12-Month Insider Activity Summary

Key Insiders

Significant Filings

AI Consult Analysis

Related Biotechnology Stocks